title: Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia.
authors.forename: S
authors.initials: S
authors.lastname: Tsiara
authors.forename: L
authors.initials: L
authors.lastname: Christou
authors.forename: P
authors.initials: P
authors.lastname: Konstantinidou
authors.forename: A
authors.initials: A
authors.lastname: Panteli
authors.forename: E
authors.initials: E
authors.lastname: Briasoulis
authors.forename: K L
authors.initials: KL
authors.lastname: Bourantas
mesh_terms: D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine